Filing Details

Accession Number:
0001415889-25-000404
Form Type:
4
Zero Holdings:
No
Publication Time:
2025-01-03 16:15:18
Reporting Period:
2025-01-01
Accepted Time:
2025-01-03 16:15:18
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1840233 Xilio Therapeutics Inc. XLO Pharmaceutical Preparations (2834) 851623397
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1971303 M. Kevin Brennan 828 Winter Street
Suite 300
Waltham MA 02451
Svp, Finance And Accounting No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2025-01-01 5,000 $0.00 5,000 No 4 M Direct
Common Stock Disposition 2025-01-02 1,803 $0.98 3,197 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Restricted Stock Units Disposition 2025-01-01 5,000 $0.00 5,000 $0.00
Common Stock Stock Option (right to buy) Acquisiton 2025-01-01 60,000 $0.00 60,000 $0.96
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
15,000 No 4 M Direct
60,000 2035-12-31 No 4 A Direct
Footnotes
  1. Restricted stock units ("RSUs) convert to stock on a one-for-one basis
  2. The reported sale of 1,803 shares occurred automatically in a "sell to cover" transaction pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 8, 2024 solely to cover tax withholding obligations in connection with the vesting of restricted stock units.
  3. These RSUs were granted on January 1, 2024 and will vest in four equal annual installments beginning on January 1, 2025 and continuing through January 1, 2028.
  4. The option was granted on January 1, 2025 and will vest in 48 equal monthly installments beginning on February 1, 2025 and continuing through January 1, 2029.